David A. Roth

机构：GlaxoSmithKline (United States) · ORCID：0000-0001-8356-0457

发表论文 278 篇 · 总被引 27077 次 · h-index 55

代表论文

• A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis (2021 · Kidney International · 被引 214)
• A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome (2022 · JCI Insight · 被引 137)
• 10 Years of belimumab experience: What have we learnt? (2021 · Lupus · 被引 135)
• Safety and Efficacy of Belimumab in Patients with Lupus Nephritis (2022 · Clinical Journal of the American Society of Nephrology · 被引 80)
• Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study (2024 · Annals of the Rheumatic Diseases · 被引 54)
• Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population (2022 · American Journal of Kidney Diseases · 被引 51)